Filament Health Corp. (FLHLF)
| Previous Close | 0.0503 |
| Open | 0.0503 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0503 - 0.0503 |
| 52 Week Range | 0.0503 - 0.3135 |
| Volume | |
| Avg. Volume | 7,090 |
| Market Cap | 9.128M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0420 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- CNW Group
FILAMENT HEALTH ANNOUNCES NEW UNITED STATES PATENT ISSUANCES
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued two new patents for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament's latest patents were issued by the United States Patent and Trademark Office (USPTO) and describe technology for transforming variable psychedelic raw materials into pharmaceutical-gr
- CNW Group
FILAMENT HEALTH ANNOUNCES PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced an agreement with the Centre for Addiction and Mental Health (CAMH), Canada's largest mental health teaching hospital and one of the world's leading research centres in the field. Filament will supply CAMH with its natural psilocybin drug candidate for a proposed clinical trial studying the effects of psilocybin for treatment-resi
- CNW Group
FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended September 30, 2022.
